Investigational drug · Phase 2
IMNN-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for SARS CoV 2 Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "IMNN-101"
First trial start
2024
Jun 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMNN-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- SARS CoV 2 Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "IMNN-101" as an intervention, largest first.
ImunonIndustry
NCT06283459 · 24 participants · Start Jun 4, 2024 · Primary completion Mar 7, 2025
Drug: IMNN-101 · For: SARS CoV 2 Infection
Sites: Boston, Massachusetts; Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.
Anwer K, Musso L, Lasrado N, et al. · Vaccine 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.